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Abstract
Introduction Agitated delirium is common in patients
undergoing mechanical ventilation, and is often treated with
haloperidol despite concerns about safety and efficacy. Use of
conventional sedatives to control agitation can preclude
extubation. Dexmedetomidine, a novel sedative and anxiolytic
agent, may have particular utility in these patients. We sought to
compare the efficacy of haloperidol and dexmedetomidine in
facilitating extubation.
Methods We conducted a randomised, open-label, parallel-
groups pilot trial in the medical and surgical intensive care unit
of a university hospital. Twenty patients undergoing mechanical
ventilation in whom extubation was not possible solely because
of agitated delirium were randomised to receive an infusion of
either haloperidol 0.5 to 2 mg/hour or dexmedetomidine 0.2 to
0.7  μg/kg/hr, with or without loading doses of 2.5 mg
haloperidol or 1 μg/kg dexmedetomidine, according to clinician
preference.
Results Dexmedetomidine significantly shortened median time
to extubation from 42.5 (IQR 23.2 to 117.8) to 19.9 (IQR 7.3 to
24) hours (P  = 0.016). Dexmedetomidine significantly
decreased ICU length of stay, from 6.5 (IQR 4 to 9) to 1.5 (IQR
1 to 3) days (P = 0.004) after study drug commencement. Of
patients who required ongoing propofol sedation, the proportion
of time propofol was required was halved in those who received
dexmedetomidine (79.5% (95% CI 61.8 to 97.2%) vs. 41.2%
(95% CI 0 to 88.1%) of the time intubated; P  = 0.05). No
patients were reintubated; three receiving haloperidol could not
be successfully extubated and underwent tracheostomy. One
patient prematurely discontinued haloperidol due to QTc interval
prolongation.
Conclusions In this preliminary pilot study, we found
dexmedetomidine a promising agent for the treatment of ICU-
associated delirious agitation, and we suggest this warrants
further testing in a definitive double-blind multi-centre trial.
Trial registration Clinicaltrials.gov NCT00505804
Introduction
Up to 71% of critically ill patients have delirium or psychomo-
tor agitation at some point in their intensive care unit (ICU) stay
[1]. Delirium is unpleasant for the patient, and is independently
associated with longer hospital stay and six-month mortality
[2]. Delirium, along with physiological disturbances (hypoxae-
mia, hypoglycaemia, drug withdrawal, etc) and pain, often
causes psychomotor agitation [3]. Agitation in intensive care
is problematic, associated with self-extubation, removal of vas-
cular catheters, increased oxygen consumption and failure to
cooperate with treatment [4].
In the early stages of a patient's intensive care treatment, delir-
ium and agitation are often masked using analgesics and sed-
atives. However, patients may remain delirious and agitated
after their underlying illness has resolved, when they are other-
wise suitable for extubation. Despite little published evidence
of efficacy, haloperidol, a centrally acting dopamine antagonist
also used in the treatment of major psychoses, is the drug rec-
APACHE: Acute Physiology and Chronic Health Evaluation; CAM-ICU: Confusion Assessment Method for the Intensive Care Unit; ICDSC: Intensive 
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ommended and most commonly prescribed for this indication
[3]. Haloperidol has a number of side effects, including
extrapyramidal reactions and (rarely) neuroleptic malignant
syndrome, although these may be due to a first-pass metabo-
lite [5], and so are less relevant with the intravenous route. The
most problematic adverse effect in the ICU is prolongation of
the corrected QT (QTc) interval [6], which can precipitate fatal
arrhythmias [7,8].
The ideal treatment for ICU-associated delirious agitation
would relieve symptoms without causing excessive sedation,
have fewer side effects than haloperidol, have little interaction
with other drugs and would be easily titrated. Analgesia could
reduce opioid use, also lessening delirium. Dexmedetomidine,
a selective α2 agonist, has all of these properties [7,9]. One
case series reported the successful use of dexmedetomidine
in this context [10], but there have been no controlled trials of
dexmedetomidine for the treatment, as opposed to prophylaxis
[11-13], of ICU-associated delirious agitation. We hypothe-
sised that dexmedetomidine would be more effective than
haloperidol in the treatment of ICU-associated delirious agita-
tion in mechanically ventilated patients. We report the results
of our pilot study assessing the feasibility of trial design and
the safety of both haloperidol and dexemedetomidine.
Materials and methods
Patients
We studied patients in our 20-bed general medical/surgical
ICU, which admits approximately 2000 patients a year, of
whom 50% undergo mechanical ventilation. The median
Acute Physiology and Chronic Health Evaluation (APACHE) III
score is 48 (interquartile range (IQR) 34 to 65), mean length
of stay is 2.8 days and mortality is 13%, which is typical of a
large Australian academic ICU [14]. From April 2006 to
August 2008 we asked clinicians to identify patients who they
considered required mechanical ventilation only because their
degree of agitation (e.g. Richmond Agitation Sedation Scale
(RASS) [15] score ≥ 2) required such a high dose of sedative
medication that extubation was not possible.
Patients were excluded if they could not be extubated even if
their agitation were corrected: for example, those receiving
high-dose opioid analgesia for pain, those with a plan to
shortly return to the operating theatre, those likely to require
ongoing airway protection or ventilatory support, and those
who remained so physiologically unstable that extubation
would be unsafe. Patients were also excluded if they had had
an adverse reaction to haloperidol or α2 agonists. Patients who
met the inclusion criteria were, by virtue of their delirium, una-
ble to give informed consent. In all cases, following the assent
of the patients' next of kin, application was made to the Victo-
rian Civil and Administrative Tribunal, who as the patients' tem-
porary legal guardian, gave consent to their enrolment. This is
the mandatory procedure in the state of Victoria for the involve-
ment in clinical research of patients unable to give consent.
The study protocol was approved by the Austin Hospital
Human Research Ethics Committee and registered with the
US Government Clinical Trials Registry (NCT00505804).
Study intervention
Eligible patients were allocated to either haloperidol or dexme-
detomidine using numbered envelopes into which a card indi-
cating patient allocation had been placed according to a
computer-generated random-number sequence. Dexmedeto-
midine was administered intravenously as a maintenance infu-
sion of 0.2 to 0.7 μg/kg/hour for as long as deemed necessary
by the treating physician. The clinician was given the option of
using a loading dose of 1.0 μg/kg intravenously over 20 min-
utes, as recommended by the manufacturer. Haloperidol was
administered as a continuous intravenous infusion of 0.5 to 2
mg/hour for as long as necessary, preceded by a loading dose
of 2.5 mg if desired.
With continuous assessment and in consultation with the
treating physician, bedside nursing staff adjusted drug infu-
sion rates as necessary (re-assessing at least every four
hours), aiming to minimise psychomotor agitation and achieve
a RASS score of 0. No rigid protocol governed the titration of
each infusion within the limits defined. Clinical personnel were
not blinded to the study drug. Treatment was continued for as
long as clinically indicated, including following extubation if
required, unless any adverse effect developed that necessi-
tated drug discontinuation. As dexmedetomdine was not on
our hospital formulary, once it had been stopped it could not
be restarted; haloperidol could be continued (by infusion or
bolus) without restriction.
Intercurrent care
No other element of patient care was affected by the trial. Cli-
nicians were free to prescribe any sedative or anxiolytic medi-
cation other than dexmedetomidine or haloperidol, and all
such medication use was recorded. Our unit has no strict pro-
tocol for the use of sedatives in intubated patients, although
patients expected to be soon weaned from mechanical venti-
lation are generally prescribed propofol, while others are given
midazolam. Intravenous lorazepam is not available in Australia.
Similarly, our unit has no formal protocol for weaning from
mechanical ventilation: the bedside nurse is responsible for
transitioning the patient from mandatory to spontaneous venti-
lation as soon as possible, with frequent (< every four hours)
assessment. The decision to extubate can occur at any time of
day or night. During the trial, the timing of tracheostomy was at
the discretion of the treating clinician, based on the clinical
impression that the patient would be likely to require pro-
longed mechanical ventilation; however, again, no objective
criteria were used.
Data collection
Upon enrolment, baseline data collected included demo-
graphic characteristics, diagnosis, APACHE II score and theAvailable online http://ccforum.com/content/13/3/R75
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use of physical restraint and sedative medication in the pre-
ceding 24 hours. During study drug infusion, clinical data were
recorded by the bedside nurses as representative values for
each four-hour period. Data collected included study drug
rate, use of other sedatives, RASS score, Intensive Care Delir-
ium Screening Checklist (ICDSC) score [16], requirement for
physical restraint, mean arterial pressure, requirement and rate
of vasopressors and inotropes, and the presence of arrhyth-
mias or any other adverse event. The QTc interval was
assessed every eight hours. Clinical data were collected until
the study drug was discontinued, and outcomes sought until
hospital discharge.
Endpoints
The primary endpoint was time from the commencement of
study drug to extubation. In the primary analysis, patients who
underwent tracheostomy were analysed as having been extu-
bated at that point (see discussion for rationale), but in a sup-
plementary analysis this was also treated as censored data.
Secondary efficacy endpoints included time from commence-
ment of study drug to ICU discharge, time taken to achieve a
satisfactory sedation score, and the need for supplemental
sedative and analgesic medication. Secondary safety end-
points included the change in QTc interval, the duration and
rate of vasopressor or inotropic support, and the requirement
for re-intubation.
Statistical analysis
Using time to extubation as the primary outcome measure, and
assuming that the mean ± standard deviation time to extuba-
tion in these agitated patients was 72 ± 20 hours, we calcu-
lated a study of 20 patients would have an 80% power of
detecting a difference in time to extubation of 24 hours in the
treatment group with a certainty of 95%. Categorical baseline
and outcome data were compared using chi-squared tests,
while continuous data was assessed graphically and com-
pared using Mann-Whitney U tests or Student's t tests as
required. Univariate survival analysis of time to extubation was
performed using the log-rank test, and a Cox proportional haz-
ards model of time to extubation was constructed using back-
ward elimination, with the initial model incorporating all listed
baseline data and the final model being that which produced
the best fit. All statistical calculations were performed using
Stata version 9.2 (StataCorp, College Station, Texas, USA).
Results
Twenty patients were recruited, with 10 allocated to dexme-
detomidine and 10 to haloperidol (Figure 1). No eligible
patients' relatives refused consent, and no patients were lost
to follow-up. There were no significant differences in the base-
line characteristics of the treatment groups (Table 1). Only
three patients were female. Eight patients received a bolus of
dexmedetomidine, and six a bolus of haloperidol (Table 2).
Patients received the intended infusion rates of their allocated
study drug almost all of the time they were intubated. Seven of
the patients randomised to dexmedetomidine had the infusion
continued after extubation; of those that continued, the median
duration was 15 (IQR 1 to 26) hours. Only four patients con-
tinued receiving haloperidol after extubation, for 6.5 (IQR 2 to
16.5) hours.
Primary endpoint
Following commencement of the study drug, patients ran-
domised to dexmedetomidine were extubated significantly
sooner than those receiving haloperidol (19.9 (IQR 7.3 to
24.0) hours vs. 42.5 (IQR 23.2 to 117.8) hours, P = 0.016;
Table 3). Three patients randomised to haloperidol eventually
underwent tracheostomy at 31, 48 and 140 hours after ran-
domisation. When these patients were excluded from the anal-
ysis, the difference in time to extubation remained significant
(dexmedetomidine 19.9 (IQR 7.3 to 24) hours vs. haloperidol
49.8 (IQR 23.2 to 117.8) hours; P = 0.0147). Time to extuba-
tion was also significantly shorter for patients receiving dexme-
detomidine in a univariate survival analysis (Figure 2); this
conclusion remained unchanged when patients undergoing
tracheostomy were censored (log rank test, n = 10 and 7, P =
0.009). The best-fit survival model adjusting for baseline differ-
ences found older age and having been on midazolam, propo-
fol or haloperidol prior to randomisation all significantly (P <
0.05) reduced the likelihood of earlier extubation. Having been
restrained prior to randomisation and a higher APACHE II
score on entry all increased the chance of early extubation.
After adjustment for all these factors, randomisation to dexme-
detomidine remained the strongest and most statistically sig-
nificant (P = 0.001) predictor of early extubation.
Secondary endpoints: efficacy
Patients who received dexmedetomidine were discharged
from the ICU significantly earlier than those randomised to
haloperidol (Table 3), and also had a shorter overall ICU length
of stay. Dexmedetomidine patients tended to achieve satisfac-
tory sedation scores more quickly, and they tended to spend a
greater proportion of time with satisfactory scores. Although
all but three patients required mechanical restraint at some
point while receiving the study drug, those randomised to
dexmedetomidine had this removed significantly earlier. Most
patients received supplemental propofol: those randomised to
dexmedetomidine required this for a significantly shorter pro-
portion of the time they were intubated (41.2% vs. 79.5%, P
= 0.05), and at a (non-significantly) lower dose.
Secondary endpoints: safety
No patients died while in the ICU, but one patient who had
received haloperidol died in the general ward from their under-
lying disease process, unrelated to study medication (Table 4).
The mean QTc interval in the two groups was no different prior
to study entry, but there was a strong trend towards more
patients in the haloperidol group having a prolongation of their
QTc interval (compared with baseline) during study drug infu-
sion. There were no significant differences in the rate or dura-Critical Care    Vol 13 No 3    Reade et al.
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Table 1
Baseline patient demographic and clinical characteristics
Dexemedetomidine Haloperidol P
N 10 10
Age, years: median (IQR) 52 (42 to 69) 68.5 (43 to 78) 0.241
Males: % 90 80 0.531
APACHE II score in the 24 hours immediately prior to enrolment: median (IQR) 13.3 (10 to 18) 15.5 (11 to 19) 0.383
Physical restraint prior to enrolment: % 80 50 0.160
Midazolam use: % 60 40 0.371
Propofol use: % 70 70 1.000
Haloperidol use: % 30 10 0.264
Morphine use: % 80 80 1.000
Other sedative or anti-psychotic use: % 0 0
Time intubated prior to randomisation, hours: median (IQR) 45.0 (34.5 to 73.3) 65.2 (28.0 to 87.0) 0.496
RASS -2 to 1 (ie. desired level of sedation and agitation control) at enrolment: % 30 10 0.264
ICDSC ≥ 4 (ie. delirium present) at enrolment: % 30 40 0.405
ICDSC ≥ 4 at any stage prior to or during infusion of trial drug: % 50 50 1.00
ICDSC > 0 (ie. at least subsyndromal delirium present) at enrolment: % 80 100 0.136
ICDSC > 0 at any stage prior to or during infusion of trial drug: % 100 100 1.00
Surgical diagnosis: % 70 30 0.074
Admission diagnosis 0.493
Pneumonia, % 0 20
Other sepsis, % 20 20
Post cardiothoracic surgery, % 30 10
Post neurosurgery, % 30 20
Other, % 20 30
APACHE = Acute Physiology and Chronic Health Evaluation; ICDSC = Intensive Care Delirium Screening Checklist; IQR = interquartile range; 
RASS = Richmond Agitation Sedation Scale.
Table 2
Interventions
Dexemedetomidine Haloperidol P
Time receiving study drug infusion while intubated, %: median (IQR) 100 (99.1 to 100.0) 94.26 (68.9 to 100.0) 0.2755
Loading dose given, % 80 60 0.329
Drug rate of infusion during the periods when it was administered: 
mean (95% CI)
0.47 (0.33 to 0.62) μg/kg/hour 1.43 (0.96 to 1.90) mg/hour N/A
Study drug continued after extubation, % 70 40 0.18
Time study drug continued after extubation, hours: median (IQR) 2.5 (0.0 to 26.0) 0.0 (0.0 to 2.0) 0.15
Of patients who continued study drug after extubation, time continued, 
hours: median (IQR)
15 (1 to 26) 6.5 (2 to 16.5) 0.57
CI = confidence interval; IQR = interquartile range.Available online http://ccforum.com/content/13/3/R75
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tion of norepinephrine required, and only two patients in each
group required the institution or a significant increase in the
rate of norepinephrine in the eight hours after study drug com-
menced. Patients who received a dexmedetomidine bolus had
no clinically significant hypotension or increased vasopressor
requirement. One patient discontinued haloperidol after
receiving 9.5 mg over 20 hours, because their consultant phy-
sician was concerned at the new onset of atrial fibrillation
immediately preceded by new prolongation of their QTc inter-
val to 0.437 seconds. There were no self-extubations, and no
patient inadvertently dislodged a central venous catheter.
There were no other reported adverse events, and no patients
required reintubation.
Discussion
This is the first study to demonstrate that dexmedetomidine is
more effective than conventional haloperidol therapy for the
treatment of combined agitation and delirium in intubated
patients in the ICU. Dexmedetomidine, in comparison to
haloperidol, safely shortened the time to extubation, reduced
ICU length of stay, hastened liberation from mechanical
restraint, reduced the need for supplementary sedation,
reduced QTc interval prolongation and possibly reduced the
need for tracheostomy.
Efficacy
In the primary analysis, we treated tracheostomy as equivalent
to extubation. We contend this is reasonable as tracheostomy
in this context represents the failure of treatment of agitation
and delirium, reflecting the clinician's decision that the patient
would be unlikely to be soon extubated. Had the three patients
in the haloperidol group not undergone tracheostomy, they
could only have remained intubated for longer; hence our anal-
ysis biases towards observing less difference between the
two groups. We nonetheless also analysed the data by exclud-
ing these patients and by treating them as censored in the sur-
vival analyses; our conclusion was unchanged.
There is a theoretical concern that given its short half-life,
when dexmedetomidine is discontinued a patient might return
to a state of agitation so severe as to require reintubation. That
none of our patients required reintubation does not discount
this possibility, given the small number we studied. We contin-
ued dexmedetomidine following extubation for as long as the
treating clinician felt the patient was at risk of reintubation due
to agitation. Had we not done so, this risk may or may not have
been manifest.
Safety
Dexmedetomidine shares no common adverse reactions with
haloperidol. Transient hypertension during the administration
of the loading dose, followed by hypotension and bradycardia,
are the only adverse reactions reported [7]. Our study was not
powered to observe anything but marked haemodynamic
effects, so we can only conclude that dexmedetomidine did
not cause a dramatic increase in vasopressor requirement.
Rationale for trial design
Dexmedetomidine has been studied and marketed primarily as
a sedative alternative to propofol or benzodiazepines. The sed-
ative, analgesic and anxiolytic effects of dexmedetomidine
have been convincingly demonstrated [9,17-20]. These trials
Figure 1
CONSORT patient flow diagram [44] []. * Intervention was discontinued because of consultant physician concern at the length of the QTc interval.Critical Care    Vol 13 No 3    Reade et al.
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were performed in the initial postoperative period and so the
approved product information limits the duration of dexme-
detomidine infusion to 24 hours [7]. However, prolonged infu-
sions have been used successfully in case series and
published trials [11-13,21,22]. We considered allowing clini-
cians to decide when to terminate the infusion would be safer
and more effective than imposing an arbitrary time limit.
Dexmedetomidine might prevent agitation by reducing the use
of other sedatives known to cause delirium [23]. In a trial
involving 106 patients, dexmedetomidine resulted in more
days alive without delirium or coma and more time at the tar-
geted level of sedation than did lorazepam [11]. However,
concerns were subsequently raised about the equivalence of
dosing [24], cost-effectiveness [25] and the validity of the out-
come measure [26]. A second trial comparing dexmedetomi-
dine to midazolam as a sedative in 375 patients found
dexmedetomidine associated with significantly less delirium
and a shorter duration of intubation [13]. However, even if
cost-effective in preventing delirium elsewhere [27], wide-
Table 3
Results: efficacy
Dexmedetomidine Haloperidol P
Primary
Time to extubation, hours: median (IQR) 19.9 (7.3 to 24.0) 42.2 (23.2 to 117.8) 0.016
Secondary
Time to ICU discharge after randomisation, days: median (IQR) 1.5 (1 to 3) 6.5 (4 to 9) 0.0039
Total ICU length of stay, days: median (IQR) 4.5 (2 to 7) 8.0 (7.0 to 11.0) 0.0093
Time taken to achieve a satisfactory RASS agitation score (-2 to 1), hours: median (IQR) 4 (0 to 7) 18 (9 to 22) 0.071
Time taken to achieve a satisfactory ICDSC score (< 4), hours: median (IQR) 0 (0 to 2) 0 (0 to 2) 0.509
Proportion of time with a satisfactory RASS agitation score (-2 to 1), %: median (IQR) 50.5 (20 to 78) 26.5 (13 to 42) 0.256
Proportion of time with a satisfactory ICDSC score (< 4) when assessable, %: median 
(IQR)
95.5 (51 to 100) 31.5 (17 to 97) 0.122
Proportion of time with a desirable ICDSC score (< 1) when assessable, %: median 
(IQR)
61.0 (0.0 to 100.0) 0.0 (0.0 to 0.0) 0.134
Required restraint at any time while on study drug, % 90 80 0.53
Of patients requiring restraint at any time while on study drug, time to first not requiring 
restraint for > 4 hours, hours: median (IQR)
18 (7.3 to 38.5) 38 (26.3 to 49.8) 0.03
Need for supplemental sedative or analgesic medication, %
Propofol 60 80 0.33
Midazolam 20 10 0.53
Morphine 30 40 0.64
Of patients requiring supplemental sedative or analgesic medication, dose rate: mean 
(95% CI)
Propofol, mg/hour 87.7 (15.5 to 160.0) 123.4 (30.4 to 216.3) 0.504
Midazolam, mg/hour 1.0 (1.0 to 1.0) 2.4 (N/A) N/A
Morphine, mg/hour 1.0 (0.5 to 1.5) 1.6 (0.3 to 2.8) 0.28
Of patients requiring supplemental sedative or analgesic medication, % time this was 
required: mean (95% CI)
Propofol 41.2 (0 to 88.2) 79.5 (61.8 to 97.2) 0.05
Midazolam 0 (0 to 0) 0 (N/A) N/A
Morphine 0 (0 to 0) 32.9 (0 to 100) 0.29
Required tracheostomy 0 3 0.06
CI = confidence interval; ICDSC = Intensive Care Delirium Screening Checklist; ICU = intensive care unit; IQR = interquartile range; RASS = 
Richmond Agitation Sedation Scale.Available online http://ccforum.com/content/13/3/R75
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spread application of dexmedetomidine as a sedative is pro-
hibitively expensive in our current context. We therefore
wondered whether dexmedetomidine might be effective in the
treatment of established delirium, reasoning that this might be
sufficiently cost-effective.
Despite widespread use and incorporation into international
guidelines [3], there is no evidence from placebo-controlled
trials supporting the use of haloperidol (or indeed any other
medication) in the management of ICU-associated delirium
[28]. Our results may therefore reflect comparison with an
ineffective agent. Olanzipine and risperidone are the only other
agents used in our management of critical illness delirium:
both have been compared with haloperidol; neither is more
effective [29,30]. We therefore concluded that, although
Figure 2
Graph showing time to extubation Graph showing time to extubation.
Table 4
Results: safety
Dexmedetomidine Haloperidol P
ICU mortality, n 0 0 1.00
Hospital mortality, n 0 1 0.31
QTc interval prior to study drug, sec: mean (95% CI) 0.411 (0.384 to 0.438) 0.426 (0.395 to 0.457) 0.41
QTc interval while on study drug, sec: mean (95% CI) 0.395 (0.365 to 0.425) 0.446 (0.423 to 0.457) 0.0061
Patients with abnormal QTc interval (> 0.440 sec) while on study drug: % 40 40 1.00
Patients with longer QTc interval than baseline while on study drug: % 30 70 0.07
Arrhythmia while on study drug: % 20 20 1.00
Patients requiring norepinephrine* infusion while on study drug: % 80 50 0.16
Patients newly requiring norepinephrine or a 20% increase in norepinephrine* 
infusion in the 8 hours after commencement of study drug: %
20 20 1.00
Of patients requiring norepinephrine, proportion of the time while on study drug 
receiving norepinephrine: mean (95%CI)
59.8 (17.9 to 100.0) 34.4 (0.0 to 87.1) 0.37
Of patients requiring norepinephrine, level of infusion (μg/min) while on study drug: 
mean (95%CI)
2.51 (0.07 to 4.90) 3.97 (0.00 to 11.07) 0.55
Any adverse event attributed to the study drug: % 0 10** 0.31
Patients requiring reintubation: n, % 0 0 1.00
* norepinephrine was the only inotropic or vasopressor medication used in any study patient
** excessive prolongation of the QTc interval, necessitating drug discontinuation
CI = confidence interval; ICU = intensive care unit; QTc = QT interval corrected for heart rate.Critical Care    Vol 13 No 3    Reade et al.
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imperfect, haloperidol represented 'standard care' in our man-
agement of delirium in the ICU.
We administered haloperidol by infusion rather than conven-
tional bolus dosing. This approach has been used successfully
in case series of ICU patients [31,32] and is presented as the-
oretically superior in current guidelines [3]. The relatively long
half-life of haloperidol (12 to 36 hours) means that control of
agitation when the infusion rate is increased may take longer
in comparison to dexmedetomidine. This concern probably
does not explain our results, as haloperidol tended to be used
at the upper end of the permitted dose in most patients for
most of the time it was infused. We chose to use haloperidol
by infusion for two main reasons. First, we were concerned
that 'on demand' boluses of haloperidol might lead to relative
underdosing compared with dexmedetomidine by continuous
infusion. Second, we designed our trial as a prelude to a larger
double-blind study, in which (to preserve blinding) both study
drugs would need to be given by continuous infusion. In the
absence of evidence, we selected a dose range of haloperidol
that reflected our usual practice. Although this was somewhat
less than the 3 to 11.35 mg/hour (in a 75 kg patient) recom-
mended by current guidelines [3], a dose of 272 mg haloperi-
dol (as per those guidelines) in a 24-hour period substantially
exceeds our routine practice. We nonetheless accept that we
may have found haloperidol less effective than dexmedetomi-
dine due to an inadequate dose.
As is the case for haloperidol, the optimal dose rate of dexme-
detomidine is also not well characterised. We used up to the
maximum dose of dexmedetomidine licensed for use in Aus-
tralia (and elsewhere) at the time of the study, which was 0.7
μg/kg/hour. Two large randomised controlled trials have now
safely used doses up to 1.4 [13] and 1.5 [11] μg/kg/hour: at
higher doses dexmedetomidine might be even more effective
for this indication.
Our study was not blinded. We were concerned at the poten-
tial for QTc interval prolongation with high doses of haloperidol
[8], particularly as continuous infusion is not our usual prac-
tice. We also noted the risk of hypotension associated with
dexmedetomidine [9], which was at the time an unfamiliar drug
in our unit. Having not observed significant complications with
either drug, we suggest a larger, blinded trial would be suffi-
ciently safe.
Strengths and limitations
This is a pilot study, with significant limitations. The principal
concern is the lack of blinding. If our consultant physicians and
bedside nurses had more confidence in dexmedetomidine
than haloperidol, they may have been more inclined to attempt
earlier extubation in dexmedetomidine patients, or proceed to
tracheostomy in patients receiving haloperidol. This is espe-
cially true given our usual clinical practice of not using objec-
tive criteria to make such decisions, although imposing such
restrictive criteria would potentially have led to a significant
change in intercurrent care. However, the observed magnitude
of the differences between the groups is difficult to attribute to
factors other than, at least in part, the different effects of the
drugs.
We allowed physicians to decide whether or not to use an ini-
tial bolus of dexmedetomidine. There is growing evidence that
such a bolus may cause adverse cardiovascular effects (hypo-
tension or hypertension) [22,33] while adding little sedation
[21,34]. Insufficient numbers may have precluded observation
of such effects. Similarly, we may have studied too few
patients to allow us to observe clinically important rebound
hypertension and tachycardia associated with the abrupt ces-
sation of dexmedetomidine. However, others have found this
quantitatively insignificant [21]. The small size of our study also
raises the possibility that our results are confounded by unob-
served imbalances in the baseline characteristics of the two
groups. Although this cannot be excluded and is inherent to
every pilot study, again the magnitude of the effect observed
adds plausibility to our findings.
We did not keep a screening log, but as our ICU admits about
1000 mechanically ventilated patients per year, it is conceiva-
ble that approximately 2300 patients were informally screened
but only 20 enrolled. At the time of the study, we, like most oth-
ers [35,36], did not routinely assess for delirium using a
screening tool. Despite its known high incidence, clinical
underdiagnosis of delirium in the ICU [37,38] partly explains
our recruiting difficulty. Additionally, we required patients be
unsuitable for extubation only because of agitation. Dexme-
detomidine may be effective in delirious patients with ongoing
physiological instability; indeed in comparison with benzodi-
azepines others have found this to be the case [11,13]. How-
ever, while there are several well-studied and effective
sedatives, we were concerned that this was not true for drugs
specifically targeting delirious agitation. Although our study
reflects use of dexmedetomidine in the context of our routine
practice at the time, we propose that any follow-up trial should
actively screen for delirium using objective criteria. Addition-
ally, we only studied patients with agitated delirium. Hypoac-
tive delirium may be eight times more common (61%) than
delirium associated with agitation (8%) [39], but, while no less
important, hypoactive delirium is difficult to identify without
active screening. The results of our pilot study do not allow us
to comment on the management of hypoactive delirium.
We have no reliable data on pre-morbid cognitive impairment
in these patients, the presence of intercurrent conditions
known to be associated with delirium or any history of sub-
stance abuse. Any imbalance in these factors between the two
groups may have confounded the results, in particular as dex-
emedetomidine may be especially useful for managing drug
withdrawal [40,41]. Having identified these potential con-Available online http://ccforum.com/content/13/3/R75
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founders, we suggest a future definitive trial examine these
factors in detail.
By chance, there were more surgical patients in the dexme-
detomidine group, although with the small size of the study this
difference was not significant. Dexmedetomidine is an analge-
sic and pain causes agitation, so dexmedetomidine may have
appeared more effective because it was a better treatment for
pain. However, in multivariate analysis, surgical diagnosis was
not a significant predictor of time to extubation, arguing
against this hypothesis.
Relatively few (50%) of our patients had delirium, as identified
by an ICDSD score of 4 or above. This is surprising, as the
impression of their treating clinicians was that each had delir-
ium as the cause of their agitation. However, Ouimet and col-
leagues [42] demonstrated that 'subsyndromal' delirium (an
ICDSC score > 0) was also associated with poor outcome,
and all of our patients has an ICDSC score more than 0 at
some point, supporting the clinical impression that they were
delirious. Although agitation is commonly caused by delirium,
this is not always the case; pain and presence of an endotra-
cheal tube alone can be sufficient to cause agitation. Some
patients were too deeply sedated at the time of enrolment to
permit proper use of the ICDSC. Presumably this sedation had
been administered because of earlier agitation, which we were
then unable to objectively record. A significant weakness of
this pilot study is therefore the lack of objective evidence of
delirium in many patients prior to randomisation, a deficiency
which should be rectified in any confirmatory trial by the use of
active screening using either the ICDSC or the Confusion
Assessment Method for the Intensive Care Unit (CAM-ICU)
[43].
Conclusions
Despite its many limitations, confidence in the results of our
study is increased by the magnitude of the effect size and by
our use of objective, easily quantified outcome measures,
which despite the listed concerns would have been difficult to
artificially manipulate. Nonetheless, given its small size and
unblinded nature, we recommend against using our conclu-
sions to support a widespread change in practice. Our study
supports, but does not conclusively demonstrate, the efficacy
and safety of dexmedetomidine at its currently licensed dose
for longer than 24 hours for this indication. We suggest our
results justify the conduct of a larger, blinded randomised con-
trolled trial, incorporating objective entry criteria and active
protocolised screening for agitated delirium, allowing use of
dexmedetomidine up to 1.5 μg/kg/hour, and incorporating for-
mal cost-effectiveness and quality-of-life analyses and follow-
up to 90 days.
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